Savara Inc. (SVRA)
NASDAQ: SVRA · Real-Time Price · USD
3.180
0.00 (0.00%)
Apr 28, 2025, 4:00 PM EDT - Market closed
Company Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases.
The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis.
The company is headquartered in Langhorne, Pennsylvania.
Savara Inc.
| Country | United States |
| Founded | 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 59 |
| CEO | Matthew Pauls |
Contact Details
Address: 1717 Langhorne Newtown Road, Suite 300 Langhorne, Pennsylvania 19047 United States | |
| Phone | 512 614 1848 |
| Website | savarapharma.com |
Stock Details
| Ticker Symbol | SVRA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001160308 |
| CUSIP Number | 805111101 |
| ISIN Number | US8051111016 |
| Employer ID | 84-1318182 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Matthew Pauls J.D., M.B.A. | Chairman and Chief Executive Officer |
| David L. Lowrance CPA | Chief Financial Officer, Chief Administrative Officer and Secretary |
| Robert Matthew Lutz M.B.A. | Chief Operating Officer |
| Kate McCabe J.D. | Chief Legal Officer |
| Anne Erickson | Chief Business Officer |
| Brian Maurer | Head of Clinical Operations |
| Charles LaPree | Executive Vice President and Head of Global Regulatory Affairs |
| Dr. Raymond Dennis Pratt FACP, M.D. | Chief Medical Officer |
| Dr. Brian Robinson M.D. | Executive Vice President of Global Medical Affairs |
| Dr. Yasmine Wasfi M.D., Ph.D. | Executive Vice President and Head of Clinical Development and Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 25, 2025 | ARS | Filing |
| Apr 25, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 25, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 25, 2025 | 10-K/A | [Amend] Annual report |
| Mar 31, 2025 | 8-K | Current Report |
| Mar 27, 2025 | SCHEDULE 13D/A | Filing |
| Mar 27, 2025 | 10-K | Annual Report |
| Mar 26, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G | Filing |
| Feb 11, 2025 | SCHEDULE 13G/A | Filing |